Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS

Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS

Mar 22, 2018
Source URL: https://qa1.novartis.us/news/media-releases/phase-iii-data-lancet-show-novartis-siponimod-significantly-improved-outcomes-patients-secondary-progressive-ms-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/phase-iii-data-lancet-show-novartis-siponimod-significantly-improved-outcomes-patients-secondary-progressive-ms-0